Company intelligence / Profile preview
POSVAX
Baltimore, Maryland, United Statesposvax.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
PosVax was a biotechnology company dedicated to developing a 'pan-HPV' vaccine designed to protect against all oncogenic types of the Human Papillomavirus. The company's core technology focused on the L2 minor capsid protein, which is more highly conserved across HPV genotypes than the L1 protein used in first-generation vaccines. By targeting L2, PosVax aimed to create a more comprehensive and cost-effective alternative to existing multi-valent vaccines. The company was founded on research from Johns Hopkins University but is no longer active, with related technology being advanced by subsequent entities. Their lead candidate, PVX-2, represented a significant attempt to simplify global HPV prevention strategies.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccineRecombinant protein
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
National Cancer Institute (NCI)Johns Hopkins University
Beyond the preview
Go deeper on POSVAX.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on POSVAX.